Top Page
AnteoTech Ltd
(Sydney:ADO)
AnteoTech Ltd (ADO) vs. iShares MSCI Australia ETF (EWA)
AnteoTech Ltd Business Overview & Revenue Model
AnteoTech Ltd Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 460.40K | 365.72K | 760.88K | 898.07K | 299.40K |
| Gross Profit | 460.40K | 365.72K | 760.88K | 898.07K | 1.27M |
| EBITDA | -11.57M | -12.35M | -12.07M | -7.18M | -4.10M |
| Net Income | -8.88M | -12.65M | -10.72M | -6.22M | -3.13M |
Balance Sheet | |||||
| Total Assets | 9.38M | 5.36M | 15.26M | 23.68M | 3.91M |
| Cash, Cash Equivalents and Short-Term Investments | 5.03M | 2.72M | 10.10M | 21.39M | 3.21M |
| Total Debt | 2.31M | 1.31M | 1.03M | 1.28M | 134.87K |
| Total Liabilities | 4.08M | 2.99M | 2.91M | 2.56M | 699.63K |
| Stockholders Equity | 5.31M | 2.38M | 12.36M | 21.11M | 3.21M |
Cash Flow | |||||
| Free Cash Flow | -7.58M | -8.77M | -11.77M | -4.76M | -2.77M |
| Operating Cash Flow | -6.52M | -8.08M | -8.65M | -4.55M | -2.50M |
| Investing Cash Flow | -1.06M | -690.83K | -3.12M | -213.07K | -270.45K |
| Financing Cash Flow | 9.89M | 1.39M | 482.29K | 22.94M | 1.71M |
AnteoTech Ltd Technical Analysis
AnteoTech Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$36.24M | ― | -36.95% | ― | ― | 11.11% | |
52 Neutral | $7.59B | 0.18 | -63.05% | 2.16% | 16.16% | 0.65% | |
50 Neutral | AU$64.65M | ― | -131.55% | ― | 12.53% | -11.04% | |
46 Neutral | $14.28M | ― | -64.72% | ― | 139.19% | 33.33% | |
44 Neutral | AU$48.70M | ― | -140.07% | ― | 62.15% | 33.93% | |
| ― | $24.49M | ― | -75.39% | ― | ― | ― | |
| ― | $26.37M | ― | -43.63% | ― | ― | ― |
AnteoTech Ltd Corporate Events
AnteoTech Ltd announced the cessation of several securities, including options that have either lapsed due to unmet conditions or expired without exercise. This development may impact the company’s capital structure and could influence investor perception, potentially affecting its market positioning and stakeholder confidence.
AnteoTech Ltd has signed a binding Term Sheet with Black Diamond Structures LLC to develop and commercialize an advanced battery product combining AnteoTech’s AnteoX™ and BDS’s MOLECULAR REBAR® technology. This collaboration aims to improve the electrochemical performance and structural integrity of high silicon anodes, targeting battery manufacturers incorporating more than 10% silicon by weight. The agreement sets the stage for a Joint Development Agreement, with production at BDS’s Texas facility and potential global expansion. This partnership is expected to accelerate value creation and deliver significant benefits to customers in the evolving LiB industry.
AnteoTech Ltd has achieved a significant milestone with its Ultranode™ X technology, reaching 890 cycles with 80% capacity retention for a 70% silicon anode. This advancement positions AnteoTech to enhance battery performance, offering benefits such as increased energy density and reduced battery size. The company is leveraging its collaboration with Mercedes-Benz and targeting EV cell manufacturers, aiming to capitalize on the growing demand for high-performance batteries in various sectors, including EVs and medical devices.
AnteoTech Ltd announced a presentation by its Chief Technology Officer, Manuel Wieser, at the 15th International Advanced Automotive Battery Conference in Mainz, Germany. The presentation, titled ‘Maximising high silicon anode performance,’ highlighted AnteoTech’s products, Anteo X™ and Ultranode™, which enhance anode integrity and support the development of next-generation high-silicon anodes for batteries. This development positions AnteoTech as a key player in the evolving automotive battery industry, aligning with the growing demand for efficient and sustainable battery technologies.
AnteoTech Ltd’s Life Sciences Business Unit is on track to achieve approximately A$0.93 million in sales for FY2025, marking a 130% increase over the previous year. The company has received a significant order from the Serum Institute of India, reflecting growing demand and a strengthening relationship. Despite some delays in the Vidcare project due to regulatory requirements, AnteoTech continues to expand its collaborations, including successful prototype development for KOMA Biotech in South Korea. These developments underscore AnteoTech’s strategic efforts to deepen customer relationships and expand its market presence.
AnteoTech Ltd has completed a strategic review resulting in significant organizational changes aimed at accelerating revenue generation and expanding market reach. Key outcomes include cost reductions, strategic partnerships, and a focus on commercializing existing products in rapidly growing markets such as E-mobility and life sciences across India, Europe, and the USA. These initiatives are expected to enhance AnteoTech’s market positioning and stakeholder trust, paving the way for future business expansion.
AnteoTech Ltd has formalized an employment agreement with Ms. Merrill Gray, who has stepped into the role of Interim CEO and Managing Director from her previous position as a Non-Executive Director. The agreement, effective from April 16, 2025, to October 16, 2025, includes a base remuneration and a daily rate for CEO services, with performance-based incentives tied to strategic milestones. This leadership transition is expected to guide the company through its strategic review and align its operations with revised strategies, potentially impacting its market positioning and stakeholder interests.
AnteoTech Ltd has announced the cessation of Mr. David Radford as a director effective April 22, 2025. Mr. Radford, through Lucremont Pty Ltd, holds significant interests in the company, including ordinary shares and a substantial number of unlisted options. This change in directorship may influence the company’s strategic direction and stakeholder interests, given Mr. Radford’s notable shareholding and involvement in the company.
AnteoTech Ltd has released its quarterly cashflow report and activities update for the period ending March 31, 2025, highlighting significant developments in its advanced battery technologies and life sciences divisions. The company is advancing its Ultranode™ technology, targeting the consumer electronics and e-Mobility markets, and is engaged in evaluations with major global chemical companies and Mercedes-Benz. In life sciences, AnteoTech is pursuing increased orders from the Serum Institute of India and negotiations with Vidcare. The company is undergoing strategic and cultural reviews to align its resources for growth, with a focus on sales, marketing, and cost management. Despite challenges in the global EV market, AnteoTech remains committed to leveraging its innovative technology suite to unlock shareholder value.